REGENEREX PHARMA, INC. 8-K

What Happened
REGENEREX PHARMA, Inc. (RGPX) filed an 8-K reporting that on March 31, 2026 the Board placed Chief Financial Officer Kenneth Perry on administrative suspension leave with pay and removed his CFO duties pending an internal review. The Board cited concerns including compliance with Board directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer for an initial 90-day term.

Key Details

• Kenneth Perry was placed on paid administrative suspension leave effective March 31, 2026; he remains an employee and will continue to receive base salary and benefits.
• The Board identified concerns about compliance with Board directives, financial oversight, corporate governance, and internal controls; the review is ongoing and no final determinations have been made.
• Don E. Ray was appointed Interim CFO effective April 1, 2026, on a 90-day initial term with an interim salary of $150,000 per year.
• Mr. Ray’s background: BBA in Accounting (University of Memphis); senior roles at George B. Jones and Dixon Hughes Goodman/Forvis Mazars; interim CFO/advisor to Price Simms Family Dealerships (2013–2019); former CFO of Diamond Automotive Group; consultant to public companies.

Why It Matters
A CFO suspension tied to questions about financial oversight and internal controls is material for investors because it could affect financial reporting, audit processes, and investor confidence. The appointment of an interim CFO aims to maintain continuity in finance operations while the Board’s review proceeds. Investors should watch for updates from the company on the review’s findings, any changes to financial reporting, and whether the interim CFO role is extended or made permanent.